Vaccines

With late-stage trials for two common eye conditions affecting millions, Cloudbreak Pharma is advancing novel drops where no approved drugs exist.

Positive Phase 1b data for two novel drugs suggests a long-acting, once-monthly oral therapy for recurrent genital herpes may be on the horizon.

An exclusive partnership between Osmind and CareNet GPO gives small practices the power of large systems, aiming to broaden patient access to advanced mental healthcare.

OncoC4 begins a landmark trial for ONC-841, a drug targeting immune cells in the brain, offering a new front in the fight against Alzheimer's disease.

A Swiss biotech's novel antibiotic has entered human trials with new funding, offering a fresh hope against the world's most dangerous superbugs.

A new paper warns that Lyme disease may pass from mother to child, a risk overlooked for decades. Researchers are now demanding urgent action and funding.

With its lead drug in Phase 3 and a strong Biogen partnership, Stoke Therapeutics prepares to update investors on its disease-modifying Dravet syndrome therapy.

A single-dose therapy wiped out aggressive glioblastoma tumors in a landmark pre-clinical study, paving the way for human trials in 2026.

With stellar trial data for its cholesterol drug obicetrapib, NewAmsterdam Pharma faces investors as it navigates a competitive market and awaits key results.

Ovid Therapeutics is spotlighting a novel drug class targeting KCC2, a key brain protein. Could this be the key to treating psychosis and epilepsy?

A US-Uruguay collaboration is using novel REJOIN-seq tech to find hidden RNA triggers of lupus, paving the way for safer, non-immunosuppressive drugs.

Ontario and Quebec expand public coverage for a potent cholesterol drug, offering a critical lifeline to thousands at risk of a second cardiovascular event.

A new report reveals a major education gap in obesity care. Informed patients are now demanding options beyond blockbuster drugs like Wegovy and Zepbound.

AIRNA has dosed the first patient with AIR-001, an RNA-editing drug that could treat both the lung and liver damage of a devastating genetic disease.

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

A novel interferon-based therapy from ABION shows promise in preclinical studies, overcoming resistance to current cancer drugs and activating the immune system.

A long-acting ketamine injection shows promise in treating severe depression without the harsh side effects and monitoring, potentially expanding access for millions.

President Trump's 100% tariff on imported drugs aims to secure the US supply chain, but the policy's success may hinge on unproven and unverified players.

Biopharma firm GENFIT sees soaring Iqirvo sales and a cash runway past 2028, overshadowing a net loss driven by strategic, non-cash write-downs.

A $10M investment from BVF Partners propels Entera Bio’s revolutionary oral osteoporosis drug into a pivotal Phase 3 trial, a major step for patients.